A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Public ClinicalTrials.gov record NCT07849231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Study identification
- NCT ID
- NCT07849231
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2026 (Estimated)
- Primary completion
- Jun 2030 (Estimated)
- Completion
- Jun 2030 (Estimated)
- Last update posted
- Oct 27, 2026
2026 – 2030
United States locations
- U.S. sites
- 25
- U.S. states
- 19
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US07 | Birmingham | Alabama | 35233 | Not yet recruiting |
| Site US26 | Gilbert | Arizona | 85234 | Not yet recruiting |
| Site US11 | Duarte | California | 91010 | Not yet recruiting |
| Site US25 | Irvine | California | 92618 | Not yet recruiting |
| Site US04 | Tampa | Florida | 33612 | Not yet recruiting |
| Site US15 | Atlanta | Georgia | 30307 | Not yet recruiting |
| Site US21 | Kansas City | Kansas | 66160 | Not yet recruiting |
| Site US18 | Baltimore | Maryland | 21287 | Not yet recruiting |
| Site US03 | Boston | Massachusetts | 02114 | Not yet recruiting |
| Site US12 | Boston | Massachusetts | 02215 | Not yet recruiting |
| Site US06 | Ann Arbor | Michigan | 48109 | Not yet recruiting |
| Site US08 | St Louis | Missouri | 63110 | Not yet recruiting |
| Site US17 | Babylon | New York | 11702 | Not yet recruiting |
| Site US01 | New York | New York | 10029 | Not yet recruiting |
| Site US02 | New York | New York | 10065 | Not yet recruiting |
| Site US14 | Charlotte | North Carolina | 28204 | Not yet recruiting |
| Site US24 | Durham | North Carolina | 27705 | Not yet recruiting |
| Site US13 | Winston-Salem | North Carolina | 27103 | Not yet recruiting |
| Site US05 | Columbus | Ohio | 43210 | Not yet recruiting |
| Site US20 | Eugene | Oregon | 97401 | Not yet recruiting |
| Site US19 | Nashville | Tennessee | 37203 | Not yet recruiting |
| Site US10 | Houston | Texas | 77030 | Not yet recruiting |
| Site US16 | Salt Lake City | Utah | 84106 | Not yet recruiting |
| Site US23 | Richmond | Virginia | 23219 | Not yet recruiting |
| Site US22 | Seattle | Washington | 98109 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07849231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07849231 live on ClinicalTrials.gov.